Ziprasidone is a second-generation antipsychotic drug developed by Pfizer. It has the same efficacy as existing second-generation antipsychotics but is notable for its lack of side effects such as weight gain and abnormal glucose metabolism. In the United States, it is listed in the guidelines as one of the first-choice drugs for schizophrenia. Having first obtained marketing approval overseas in 1998 (2001 in the U.S.), it is now prescribed to schizophrenia patients in 76 countries and regions and is a drug with ample dosage experience (it has obtained marketing approval in 92 countries). In Japan, it has completed Phase 1, and results indicate that there are no ethnic differences between Westerners and Japanese in pharmacokinetics and safety.

This program is the subject of a licensing agreement with Meiji Seika Pharma, Co., Ltd. For details, please see the Licensing Status link.